ERBB2 and neoplasm: However, tumor regression following oncogene inactivation has been observed in response to targeted therapeutics in humans including molecules that target BCR-ABL or c-Kit, EGFR, ALK, BRAF V600E, PML-RARα, and HER2/neu for the treatment of leukemia, lung adenocarcinoma, non-small cell lung cancer, melanoma, and breast cancer [15-23].